Table 2.
Sojourn times and Normalized Transition Rates (NTR) in the steady phase
| Steady phase (2001–7200 s) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Group | WAKE | NREM | REM | ||||||
| Sojourn time (s) | L | U | Sojourn time (s) | L | U | Sojourn time (s) | L | U | |
| RD-SSRI | 25.939 *# | 22.668 | 29.681 | 49.719 | 44.440 | 55.625 | 43.633 #& | 35.921 | 53.001 |
| HC-SSRI | 17.051 | 14.901 | 19.511 | 54.452 | 48.670 | 60.921 | 65.816 * | 54.183 | 79.946 |
| RD-VEH | 23.081 * | 20.442 | 26.061 | 40.459 | 36.157 | 45.273 | 20.999 * | 18.379 | 23.994 |
| HC-VEH | 17.199 | 15.031 | 19.681 | 46.758 | 41.793 | 52.312 | 32.844 | 27.039 | 39.896 |
| WAKE → NREM | NREM → WAKE | ||||||||
| NTR | L | U | NTR | L | U | ||||
| RD-SSRI | 0.631 *# | 0.528 | 0.755 | 0.836 | 0.696 | 1.005 | |||
| HC-SSRI | 0.970 | 0.819 | 1.150 | 0.938 | 0.800 | 1.099 | |||
| RD-VEH | 0.685 * | 0.573 | 0.819 | 0.831 * | 0.695 | 0.993 | |||
| WAKE → REM | REM → WAKE | ||||||||
| NTR | L | U | NTR | L | U | ||||
| RD-SSRI | 0.940 | 0.562 | 1.573 | 0.820 | 0.535 | 1.255 | |||
| HC-SSRI | 1.347 | 0.822 | 2.206 | 0.518 * | 0.282 | 0.951 | |||
| RD-VEH | 1.277 | 0.768 | 2.123 | 1.208 | 0.853 | 1.710 | |||
| NREM → REM | REM → NREM | ||||||||
| NTR | L | U | NTR | L | U | ||||
| RD-SSRI | 1.274 #& | 0.975 | 1.665 | 0.709 & | 0.497 | 1.013 | |||
| HC-SSRI | 0.605 * | 0.453 | 0.806 | 0.486 * | 0.297 | 0.796 | |||
| RD-VEH | 2.198 * | 1.739 | 2.779 | 1.796 * | 1.382 | 2.334 | |||
Sojourn time: the estimated mean of the average time span of an event;
Normalized Transition Rate (NTR): relative transition rate compared to the HC-VEH group (NTR of the HC-VEH group is 1);
L and U: lower and the upper limits of the corresponding 95% confidence interval, respectively;
* p < 0.05, significant effect compared to the HC-VEH group;
# p < 0.05, significant effect compared to the HC-SSRI group;
& p < 0.05, significant effect compared to RD-VEH group;
Groups: home cage plus chronic vehicle treatment (HC-VEH); home cage plus chronic escitalopram treatment (HC-SSRI); REM sleep deprivation plus chronic vehicle treatment (RD-VEH); REM sleep deprivation plus chronic escitalopram treatment (RD-SSRI).